Last reviewed · How we verify
Yttrium Muriaticum (YTTRIUM)
At a glance
| Generic name | YTTRIUM |
|---|---|
| Sponsor | Hahnemann Laboratories, INC. |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma (PHASE2)
- A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepatocellular Carcinoma Amenable to TARE (PHASE2)
- Scout Dose of Resin Microspheres (NA)
- Yttrium Y-90 Radioembolization in Treating Patients With Metastatic Liver Cancer (PHASE1)
- A Comparative Study Between the Usage of Flexible and Navigable Suction Ureteral Access Sheath Versus Traditional Access Sheath in Retrograde Intrarenal Surgeries (NA)
- Yttrium-90 (Y90) Radioembolization for the Treatment of Early Stage Renal Cell Carcinoma, The RENEGADE Trial (PHASE1,PHASE2)
- YAG Laser Vitreolysis for Vitreous Floaters (NA)
- Study of Tebentafusp and Radioembolization in the Treatment of Metastatic Uveal Melanoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Yttrium Muriaticum CI brief — competitive landscape report
- Yttrium Muriaticum updates RSS · CI watch RSS
- Hahnemann Laboratories, INC. portfolio CI